Compare BTDR & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTDR | HRMY |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2021 | 2020 |
| Metric | BTDR | HRMY |
|---|---|---|
| Price | $8.09 | $27.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 10 |
| Target Price | $25.10 | ★ $46.70 |
| AVG Volume (30 Days) | ★ 8.7M | 1.1M |
| Earning Date | 02-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 2.71 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $72.51 | $19.87 |
| Revenue Next Year | $40.84 | $12.49 |
| P/E Ratio | ★ N/A | $10.32 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $6.84 | $25.52 |
| 52 Week High | $27.80 | $40.87 |
| Indicator | BTDR | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 42.21 | 33.54 |
| Support Level | $7.30 | $27.66 |
| Resistance Level | $14.74 | $28.99 |
| Average True Range (ATR) | 0.61 | 0.74 |
| MACD | 0.26 | 0.22 |
| Stochastic Oscillator | 32.62 | 34.04 |
Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.